TAVNEOS — Finite-lived intangible assets, gross
Products & Services · Finite-lived intangible assets, grossAnalysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2025
Last reportedQ4 2025
How to read this metric
An increase indicates recent acquisitions or capital investments in product rights, while a decrease reflects the impairment or write-off of these assets. High gross values relative to revenue may suggest significant upfront investment in external innovation.
Detailed definition
This metric represents the total historical cost of acquired intellectual property, patents, or product rights associate...
Peer comparison
Comparable to 'Acquired Product Rights' or 'Intangible Assets' reported by other biotechnology firms following M&A activity or licensing deals.
Metric ID:
amgn_segment_tavneos_finite_lived_intangible_assets_grossHistorical Data
1 periods
| Q4 '25 | |
|---|---|
| Value | $2.50B |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's tavneos — finite-lived intangible assets, gross?
- Amgen (AMGN) reported tavneos — finite-lived intangible assets, gross of $2.50B in Q4 2025.
- What does tavneos — finite-lived intangible assets, gross mean?
- The total original cost of acquired product rights and intellectual property for the TAVNEOS therapeutic line.